These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 4146205)

  • 1. Inhibition of the anticonvulsant activity of L-dopa by FLA-63, a dopamine- -hydroxylase inhibitor.
    McKenzie GM; Soroko FE
    J Pharm Pharmacol; 1973 Jan; 25(1):76-7. PubMed ID: 4146205
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence for a centrally mediated hypotensive effect of L-dopa in the rat.
    Henning M; Rubenson A
    J Pharm Pharmacol; 1970 Mar; 22(3):241-3. PubMed ID: 4399501
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversal by L-DOPA of the suppression of locomotor activity induced by inhibition of tyrosine-hydroxylase and DA-beta-hydroxylase in mice.
    Ahlenius S
    Brain Res; 1974 Mar; 69(1):57-65. PubMed ID: 4150408
    [No Abstract]   [Full Text] [Related]  

  • 4. Increased dopamine concentration in the striatum in the mouse by FLA-63, a dopamine- -hydroxylase inhibitor.
    Svensson TH
    J Pharm Pharmacol; 1973 Jan; 25(1):73-5. PubMed ID: 4146204
    [No Abstract]   [Full Text] [Related]  

  • 5. The effects of DOPA on the visual-evoked potentials in rabbit and on mouse motor behavior following inhibition of dopamine-beta-hydroxylase.
    Sabelli HC; Giardina WJ; Myles SB; Vazquez AJ
    Arzneimittelforschung; 1974 Mar; 24(3):333-7. PubMed ID: 4407412
    [No Abstract]   [Full Text] [Related]  

  • 6. The anticonvulsant action of methazolamide in mice: antagonism by various inhibitors of dopamine beta-hydroxylase.
    Lotti VJ; Torchiana ML; Stone CA
    Eur J Pharmacol; 1977 Aug; 44(4):387-90. PubMed ID: 19268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new dopamine- -hydroxylase inhibitor: effects on the noradrenaline concentration and on the action of L-DOPA in the spinal cord.
    Andén NE; Fuxe K
    Br J Pharmacol; 1971 Dec; 43(4):747-56. PubMed ID: 4339882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Some characteristics of amnesia induced by FLA-63 an inhibitor of dopamine beta hydroxylase.
    Botwinick CY; Quartermain D; Freedman LS; Hallock MF
    Pharmacol Biochem Behav; 1977 May; 6(5):487-91. PubMed ID: 19771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proceedings: The mechanism of the effect of dopamine-beta-hydroxylase inhibitor FLA-63 on the L-DOPA reversal of reserpine akinesia.
    Dolphin A; Jenner P; Marsden CD
    Br J Pharmacol; 1975 Jun; 54(2):246P-247P. PubMed ID: 1148534
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparison of centrally mediated hypotensive action of methyldopa and DOPA in cats.
    Torchiana ML; Lotti VJ; Clark CM; Stone CA
    Arch Int Pharmacodyn Ther; 1973 Sep; 205(1):103-13. PubMed ID: 4148405
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacological and metabolic interactions between ethanol and the dopamine-beta-hydroxylase inhibitor FLA 63 in mice.
    Sharkawi M
    Neuropharmacology; 1980 Mar; 19(3):277-80. PubMed ID: 6999373
    [No Abstract]   [Full Text] [Related]  

  • 12. Mechanism of inhibition of dopamine beta-hydroxylase evoked by FLA-63. An in vitro study.
    Brodde OE; Nagel M; Schümann HJ
    Arch Int Pharmacodyn Ther; 1977 Aug; 228(2):184-90. PubMed ID: 921409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dopamine-beta-hydroxylase inhibitors 1,1-dimethyl-3-phenyl-2-thiourea, fusaric acid and dimethyldithiocarbamate, on the rat brain monoamine content following intraventricular injection of L-dopa.
    Vetulani J; Reichenberg K
    Biochem Pharmacol; 1973 Jun; 22(11):1263-8. PubMed ID: 4727781
    [No Abstract]   [Full Text] [Related]  

  • 14. Antagonism by DL-threo-DOPS of the suppression of a conditioned avoidance response induced by a dopamine-beta-hydroxylase inhibitor.
    Ahlenius S; Engel J
    J Neural Transm; 1973; 34(4):267-77. PubMed ID: 4359658
    [No Abstract]   [Full Text] [Related]  

  • 15. Influence of the dopamine-beta-hydroxylase inhibitor FLA 63 on the disposition of barbitone in the mouse.
    Sharkawi M
    J Pharm Pharmacol; 1979 May; 31(5):340-1. PubMed ID: 37309
    [No Abstract]   [Full Text] [Related]  

  • 16. Enhancement of noradrenaline turnover in rat brain by L-dopa.
    Keller HH; Bartholini G; Pletscher A
    J Pharm Pharmacol; 1974 Aug; 26(8):649-51. PubMed ID: 4155736
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of the dopamine-beta-hydroxylase inhibitor FLA 63 on the kinetics of elimination of amphetamine in the rat.
    Jonsson J; Lewander T
    J Pharm Pharmacol; 1974 Nov; 26(11):907-9. PubMed ID: 4156566
    [No Abstract]   [Full Text] [Related]  

  • 18. Increase of brain levels of tryptophan induced by inhibition of dopamine beta-hydroxylase (EC 1.14.2.1).
    Johnson GA; Kim EG
    J Neurochem; 1973 Jun; 20(6):1761-4. PubMed ID: 4719318
    [No Abstract]   [Full Text] [Related]  

  • 19. Dopamine nerve terminals in the rat limbic cortex: aspects of the dopamine hypothesis of schizophrenia.
    Hökfelt T; Ljungdahl A; Fuxe K; Johansson O
    Science; 1974 Apr; 184(4133):177-9. PubMed ID: 4856104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anticonvulsant action of the carbonic anhydrase inhibitor methazolamide: possible involvement of a noradrenergic mechanism.
    Gray WD; Rauh CE
    Eur J Pharmacol; 1974 Sep; 28(1):42-54. PubMed ID: 4154204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.